THE DEAL, AT A GLANCE
From the announcementInhibrx
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedInhibrx raised $200M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersInhibrx is using Growth Round capital to move a rare-disease protein therapeutics pipeline from Phase 1 evidence toward later-stage clinical validation.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Inhibrx · Financing Record
Explore source-linked visual explanations for Inhibrx. Unsupported claims are withheld while source review continues.
Record 1644 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →